In Vivo
CRISPR is the therapy
GENETIC DISEASES
Dosed first ATTR patient in November 2020 with single-course, CRISPR/Cas9-based therapy, NTLA-2001.
Learn more about our in vivo programs.
Program
Research
Candidate Selection
IND-Enabling
Phase 1
Phase 2
Phase 3
Partner
NTLA-2001:
Transthyretin Amyloidosis
Learn more
Phase 1
NTLA-2002:
Hereditary Angioedema
Learn more
IND-Enabling
Hemophilia A and B
Learn more
Research
Research Programs
Learn more
Research
Research Programs
Learn more
Research
* Lead development and commercial party
** Rights to certain in vivo targets
Last Updated: October 19, 2020
Ex Vivo
CRISPR creates the therapy
IMMUNO-ONCOLOGY / AUTOIMMUNE DISEASE
We expect to submit an IND or IND-equivalent in 1H 2021 for WT1-directed TCR T cell therapy, NTLA-5001 for the treatment of AML.
Learn more about our ex vivo programs.
Program
Research
Candidate Selection
IND-Enabling
Phase 1
Phase 2
Phase 3
Partner
OTQ923 / HIX763:
Sickle Cell Disease
Learn more
Phase 1/2
Phase 1/2
NTLA-5001:
Acute Myeloid Leukemia
Learn more
IND-Enabling
Solid Tumors
Learn more
Research
Undisclosed Programs
Learn more
Research
Other Novartis Programs
Undisclosed
*** Milestones & royalties
Last Updated: October 19, 2020
